Seattle Genetics has added Abbott to its list of collaborators for its antibody-drug conjugate (ADC) technology. Abbott will pay US$8 M upfront to utilise Seattle Genetics’ ADC technology with antibodies to a single oncology target. Seattle Genetics could also receive up to approximately US$200 M in milestones and royalties on global net sales of any ADC products that result from the collaboration.